Prescribing Patterns and Effectiveness of Ceftolozane/Tazobactam in Immunosuppressed Patients

academic.oup.com February 4, 2025

Treatment with Ceftolozane/Tazobactam (C/T) resulted in a high rate of clinical success in this real-world cohort of immunosuppressed patients, despite dosing that frequently deviated from labelled dosing.

Pseudomonas aeruginosa including MDR isolates were frequently identified.

Based on these results C/T is a useful option for the treatment of GN infections including those due to MDR PsA in the immunosuppressed patient population.

SPECTRA (Study of Prescribing patterns and Effectiveness of Ceftolozane/Tazobactam [C/T] Real-world Analysis) was a multicenter observational study conducted in 7 countries, with patients (age≥18yrs) who received ≥48-hours C/T treatment (n=617).

Medical records were extracted covering a 6-month period prior to the index date, up to 30 days after the last dose of C/T or until death.